Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours

Inclusion Criteria:

• 18 years or older

• histologically or cytologically confirmed advanced or refractory solid tumour and nolonger eligible for approved, available standard therapies. Tumour types must have:

1. proven MET activating mutations, determined by previous next generationsequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, or

2. proven amplification (≥ 10 copies) on archived tumour tissue. or

3. Hereditary Renal Papillary Cancer

• measurable disease in accordance with RECIST 1.1

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

• adequate bone marrow function, without the support of cytokines

• adequate liver function

• adequate renal function

• agree to follow the contraception requirements of the trial

• signed informed consent, indicating study patients understand the purpose of andprocedures required for the study and are willing to participate in the study.

Exclusion Criteria:

• major surgery within 3 weeks before enrollment

• chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks),radiotherapy, immunotherapy, or any other study drug within 3 weeks before studydrug administration

• antibody based cancer therapy within 4 weeks before administration of the first doseof DO-2

• patients who became progressive on previous treatment with a MET-kinase inhibitor

• patients with brain metastases are excluded unless all of the following criteria aremet:

1. CNS lesions are asymptomatic and previously treated

2. No ongoing requirement for corticosteroids as therapy for CNS metastases

3. Imaging demonstrates stability of disease > 28 days from last treatment for CNSmetastases

• leptomeningeal involvement (leptomeningeal carcinomatosis)

• history of uncontrolled heart disease including unstable angina, congestive heartfailure, myocardial infarction within preceding 12 months, clinically significantrhythm or conduction abnormality, congenital long QT syndrome, obligate use of acardiac pacemaker, QTc at screening greater than 450 milliseconds in males andgreater than 470 milliseconds in females

• uncontrolled arterial hypertension despite appropriate therapy

• positive pregnancy test (urinary beta-hCG) at screening (applicable to women ofchild-bearing potential who are sexually active)

• mental status alteration or history of major psychiatric illness, which maypotentially impair patient's compliance with study procedures

• signs and symptoms of active infection requiring systemic therapy

• other medical condition (e.g. pre-existing kidney dysfunction) that in the opinionof the investigator makes it undesirable for a patient to participate